These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31127821)

  • 1. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.
    Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3437-3449. PubMed ID: 31127821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-dependent Cushing syndrome patients.
    Bonnet-Serrano F; Poirier J; Vaczlavik A; Laguillier-Morizot C; Blanchet B; Baron S; Guignat L; Bessiene L; Bricaire L; Groussin L; Assié G; Guibourdenche J; Bertherat J
    Eur J Endocrinol; 2022 Aug; 187(2):315-322. PubMed ID: 35699971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing's Syndrome Treatment.
    Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
    J Clin Endocrinol Metab; 2021 Mar; 106(4):e1618-e1630. PubMed ID: 33399817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
    Varlamov EV; Han AJ; Fleseriu M
    Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.
    Detomas M; Altieri B; Deutschbein T; Fassnacht M; Dischinger U
    Front Endocrinol (Lausanne); 2022; 13():903545. PubMed ID: 35769081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selectivity of osilodrostat as an inhibitor of human steroidogenic cytochromes P450.
    Valentín-Goyco J; Liu J; Peng HM; Oommen J; Auchus RJ
    J Steroid Biochem Mol Biol; 2023 Jul; 231():106316. PubMed ID: 37098354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of Cushing's syndrome with steroid biosynthesis inhibitors.
    Engelhardt D; Weber MM
    J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):261-7. PubMed ID: 8043488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disorganized Steroidogenesis in Adrenocortical Carcinoma, a Case Study.
    Uchida T; Nishimoto K; Fukumura Y; Asahina M; Goto H; Kawano Y; Shimizu F; Tsujimura A; Seki T; Mukai K; Kabe Y; Suematsu M; Gomez-Sanchez CE; Yao T; Horie S; Watada H
    Endocr Pathol; 2017 Mar; 28(1):27-35. PubMed ID: 27430645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osilodrostat: 11β-hydroxylase inhibitor for treatment of Cushing's disease.
    Paton DP
    Drugs Today (Barc); 2020 Oct; 56(10):643-654. PubMed ID: 33185629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming growth factor beta1 inhibits aldosterone and cortisol production in the human adrenocortical cell line NCI-H295R through inhibition of CYP11B1 and CYP11B2 expression.
    Liakos P; Lenz D; Bernhardt R; Feige JJ; Defaye G
    J Endocrinol; 2003 Jan; 176(1):69-82. PubMed ID: 12525251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11 beta-hydroxylase.
    Engelhardt D; Dörr G; Jaspers C; Knorr D
    Klin Wochenschr; 1985 Jul; 63(13):607-12. PubMed ID: 2993735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cushing's disease: adrenal steroidogenesis inhibitors.
    Pivonello R; Simeoli C; Di Paola N; Colao A
    Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approach to the Patient Treated with Steroidogenesis Inhibitors.
    Castinetti F; Nieman LK; Reincke M; Newell-Price J
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors.
    Mangelis A; Jühlen R; Dieterich P; Peitzsch M; Lenders JWM; Hahner S; Schirbel A; Eisenhofer G
    J Steroid Biochem Mol Biol; 2019 Apr; 188():38-47. PubMed ID: 30529282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells.
    Lamberts SW; Bons EG; Bruining HA; de Jong FH
    J Pharmacol Exp Ther; 1987 Jan; 240(1):259-64. PubMed ID: 3027305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome.
    Valassi E; Aulinas A; Glad CA; Johannsson G; Ragnarsson O; Webb SM
    Clin Endocrinol (Oxf); 2017 Nov; 87(5):433-439. PubMed ID: 28665508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osilodrostat oral tablets for adults with Cushing's disease.
    Martino M; Aboud N; Lucchetti B; Salvio G; Arnaldi G
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):99-109. PubMed ID: 35220871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluconazole inhibits human adrenocortical steroidogenesis in vitro.
    van der Pas R; Hofland LJ; Hofland J; Taylor AE; Arlt W; Steenbergen J; van Koetsveld PM; de Herder WW; de Jong FH; Feelders RA
    J Endocrinol; 2012 Dec; 215(3):403-12. PubMed ID: 23038793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiological and drug-induced changes in blood levels of adrenal steroids and their precursors in cynomolgus monkeys: An application of steroid profiling by LC-MS/MS for evaluation of the adrenal toxicity.
    Tochitani T; Yamashita A; Matsumoto I; Kouchi M; Fujii Y; Yamada T; Miyawaki I
    J Toxicol Sci; 2019; 44(9):575-584. PubMed ID: 31474739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Utility of Osilodrostat in Cushing's Disease: Review of Currently Available Literature.
    Perosevic M; Tritos NA
    Drug Des Devel Ther; 2023; 17():1303-1312. PubMed ID: 37143705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.